Photo: Depositphotos
Jun 25, 2025, 07:56
Tuğba Başoğlu: A New Chapter for ADCs in EGFR+ NSCLC Begins
Tuğba Başoğlu, Associate Professor at Kartal Dr. Lutfi Kirdar City Hospital, shared Oncology Brothers’s post on X:
“FDA approval alert!
Dato-DXd has been approved for previously treated EGFR-mutant NSCLC based on pooled data from tropionlung 01 and 05.
- ORR: 43%
- mDOR: 7.0 mo
- mPFS: 5.8 mo
- mOS: 15.6 mo
A new chapter for ADCs in EGFR+ NSCLC begins.”
Quoting Oncology Brothers’s post:
“Datopotamab deruxtecan (DatoDXd – Trop2 ADC) now FDA Oncology approved off TROPION Lung 01 and 05 for previously treated mEGFR NSCLC
- ORR of 42.7%, mDoR 7.0 mos
- mPFS: 5.8 mos and mOS 15.6 mos
- AEs: Nausea, stomatitis, and ILD”
An interesting article about NSCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 25, 2025, 07:56
Jun 25, 2025, 07:49
Jun 25, 2025, 07:33
Jun 25, 2025, 07:10